Back to Search
Start Over
Overexpression of miR-26b decreases the cisplatin-resistance in laryngeal cancer by targeting ATF2
- Source :
- Oncotarget
- Publication Year :
- 2017
- Publisher :
- Impact Journals, LLC, 2017.
-
Abstract
- // Linli Tian 1 , Jiarui Zhang 1 , Xiuxia Ren 1 , Xinyu Liu 1 , Wei Gao 1 , Chen Zhang 1 , Yanan Sun 1 and Ming Liu 1 1 Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China, 150086 Correspondence to: Ming Liu, email: haerbinmingliu@21cn.com Keywords: laryngeal cancer, Hep-2/R, miR-26b, ATF2, cisplatin Received: July 10, 2017 Accepted: August 09, 2017 Published: September 08, 2017 ABSTRACT Cisplatin is a common used chemotherapeutic drug for the treatment of laryngeal cancer. However, drug-resistance is a major obstacle in platinum-based chemotherapy for laryngeal cancer. Recent studies have demonstrated that dysregulation of microRNAs (miRNAs) is responsible for chemoresistance in multiple cancers including laryngeal cancer, but the potential mechanisms are required to be explored. In the present study, we constantly exposed the laryngeal cancer cell line Hep-2 with cisplatin to establish a cisplatin-resistant laryngeal cancer cell model (Hep-2/R). We found that Hep-2/R cells exhibited obvious resistance to cisplatin compared to the Hep-2 cells. However, overexpression of miR-26b significantly decreased the half maximal inhibitory concentration (IC50) of cisplatin to Hep-2/R. Mechanically, miR-26b in Hep-2/R decreased the expression of ATF2, and thus inhibiting the phosphorylation of ATF2 and formation of cellular ATF2-c-Jun complex induced by cisplatin. As the results, Hep-2/R cells failed to overexpress the Bcl-xl which is a key anti-apoptotic protein under the cisplatin treatment. Therefore, overexpression of miR-26b was found to be able to promote mitochondrial apoptosis induced by cisplatin.
- Subjects :
- miR-26b
0301 basic medicine
Pathology
medicine.medical_specialty
medicine.medical_treatment
cisplatin
03 medical and health sciences
0302 clinical medicine
microRNA
ATF2
Medicine
Hep-2/R
IC50
Cisplatin
Chemotherapy
business.industry
Cancer
medicine.disease
030104 developmental biology
Oncology
Apoptosis
030220 oncology & carcinogenesis
Cancer cell
Cancer research
laryngeal cancer
Phosphorylation
business
Research Paper
medicine.drug
Subjects
Details
- ISSN :
- 19492553
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Oncotarget
- Accession number :
- edsair.doi.dedup.....61fff08640a5be78e82adbbfde9998f1